215 related articles for article (PubMed ID: 24023754)
1. Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).
Mudaliar MA; Haggart RD; Miele G; Sellar G; Tan KA; Goodlad JR; Milne E; Vail DM; Kurzman I; Crowther D; Argyle DJ
PLoS One; 2013; 8(9):e72591. PubMed ID: 24023754
[TBL] [Abstract][Full Text] [Related]
2. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
3. Assessment of canonical NF-κB activity in canine diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Mason NJ
Methods Mol Biol; 2015; 1280():469-504. PubMed ID: 25736768
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.
Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M
Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222
[TBL] [Abstract][Full Text] [Related]
5. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
Nogai H; Wenzel SS; Hailfinger S; Grau M; Kaergel E; Seitz V; Wollert-Wulf B; Pfeifer M; Wolf A; Frick M; Dietze K; Madle H; Tzankov A; Hummel M; Dörken B; Scheidereit C; Janz M; Lenz P; Thome M; Lenz G
Blood; 2013 Sep; 122(13):2242-50. PubMed ID: 23869088
[TBL] [Abstract][Full Text] [Related]
6. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
7. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
[TBL] [Abstract][Full Text] [Related]
8. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.
Richards KL; Motsinger-Reif AA; Chen HW; Fedoriw Y; Fan C; Nielsen DM; Small GW; Thomas R; Smith C; Dave SS; Perou CM; Breen M; Borst LB; Suter SE
Cancer Res; 2013 Aug; 73(16):5029-39. PubMed ID: 23783577
[TBL] [Abstract][Full Text] [Related]
9. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
10. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
11. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
[TBL] [Abstract][Full Text] [Related]
12. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
13. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.
Habineza Ndikuyeze G; Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Flood P; Krick E; Propert KJ; Mason NJ
PLoS One; 2014; 9(5):e95404. PubMed ID: 24798348
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA
Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134
[TBL] [Abstract][Full Text] [Related]
16. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
[TBL] [Abstract][Full Text] [Related]
17. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
[TBL] [Abstract][Full Text] [Related]
18. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
19. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Sierra J; Prat J
Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
[TBL] [Abstract][Full Text] [Related]
20. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]